Exonhit Announces Successful Completion of the Second Phase of EHT Dx14 Clinical Validation

EHT Dx14 determinates the exact nature of breast tumors in more than 90% of cases

21-Jul-2011 - France

Following the first data in benign and malignant fine-needle aspiration (FNA) samples, Exonhit announced successful completion of the second phase of the validation study of EHT Dx14, a new transcriptomic signature allowing to differentiate, at molecular level, benign breast tumors from malignant ones.

“These excellent results confirm EHT Dx14 ability to identify in almost 80% of indeterminate FNA samples the exact nature of breast tumor. These results combined together with those obtained in benign and malignant FNA samples give a global performance greater than 90% for the test, “ said Loïc Maurel, M.D., President of the Management Board of Exonhit. “EHT Dx14 development demonstrates the power of our technology in the development of high performing molecular signatures.”

“These results show that EHT Dx14, in association with cytological analysis, could become an alternative to the use of breast biopsies in a large number of cases. They also open very interesting perspectives for strengthening cytology positioning in its contribution to establishing breast cancer diagnosis,” added Philippe Vielh, M.D., Head of the Cytopathological Unit in the Department of Biopathology at the Institut Gustave Roussy in Villejuif (France).

EHT Dx14 clinical validation was a two-step process. It first demonstrated in an independent set of malignant (47) and benign (47) FNA samples coming from the Institut Gustave Roussy biobank, a specificity of 91.5% and a sensitivity of 97.9%.

The purpose of the second validation step was to demonstrate the added value of the test in the discrimination of 55 “difficult” samples for which the cytological analysis did not allow to conclude as it relates to the malignant or benign nature of the sample. The results showed a specificity of 81.8% and a sensitivity of 77.3%. Hence, when cytological analysis gives indeterminate results, EHT Dx14 is able to define the exact nature of breast tumor in close to 4 cases out of 5.

By projection, taking into account the expected frequency of uncertain diagnosis in the general population, the adjusted global performance of EHT Dx14 is 93.4% (post hoc analysis); its specificity is 90.7% and its sensitivity, 96.1%. The test performance adjusted to the Institut Gustave Roussy prevalence is greater than 90% hence demonstrating the excellent performance of EHT Dx14 on the global FNA population processed at Institut Gustave Roussy.

https://www.analytica-world.com/en/news/133638/exonhit-announces-successful-completion-of-the-second-phase-of-eht-dx14-clinical-validation.html